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Abstract 
Autism spectrum disorder (ASD) is a highly heritable and heterogeneous group of 
neurodevelopmental phenotypes diagnosed in more than 1% of children. Common genetic 
variants contribute substantially to ASD susceptibility, but to date no individual variants 
have been robustly associated with ASD. With a marked sample size increase from a unique 
Danish population resource, we report a genome-wide association meta-analysis of 18,381 
  
ASD cases and 27,969 controls that identifies five genome-wide significant loci. Leveraging 
GWAS results from three phenotypes with significantly overlapping genetic architectures 
(schizophrenia, major depression, and educational attainment), seven additional loci shared 
with other traits are identified at equally strict significance levels.  Dissecting the polygenic 
architecture we find both quantitative and qualitative polygenic heterogeneity across ASD 
subtypes. These results highlight biological insights, particularly relating to neuronal 
function and corticogenesis and establish that GWAS performed at scale will be much more 
productive in the near term in ASD. 
 
ASD is the term for a group of pervasive neurodevelopmental disorders characterized by 
impaired social and communication skills along with repetitive and restrictive behavior. The 
clinical presentation is very heterogeneous including individuals with severe impairment and 
intellectual disability as well as individuals with above average IQ and high levels of 
academic and occupational functioning. ASD affects 1-1.5% of individuals and is highly 
heritable, with both common and rare variants contributing to its etiology1-4. Common 
variants have been estimated to account for a major part of ASD liability2 as has been 
observed for other common neuropsychiatric disorders.  By contrast, de novo mutations, 
mostly copy number variants (CNVs) and gene disrupting point mutations, have larger 
individual effects, but collectively explain <5% of the overall liability1-3 and far less of the 
heritability. While a number of genes have been convincingly implicated via excess 
statistical aggregation of de novo mutations, the largest GWAS to date (n=7387 cases 
scanned) – while providing compelling evidence for the bulk contribution of common 
variants – did not conclusively identify single variants at genome-wide significance5-7. This 
underscored that common variants, as in other complex diseases such as schizophrenia, 
  
individually have low impact and that a substantial scale-up in sample numbers would be 
needed. 
 
Here we report the first common risk variants robustly associated with ASD by more than 
doubling the discovery sample size compared to previous GWAS5-8. We describe strong 
genetic correlations between ASD and other complex disorders and traits, confirming shared 
etiology, and we show results indicating differences in the polygenic architecture across 
clinical sub-types of ASD. Leveraging these relationships and recently introduced 
computational techniques9, we identify additional novel ASD-associated variants that are 
shared with other phenotypes. Furthermore, by integrating with complementary data from 
Hi-C chromatin interaction analysis of fetal brains and brain transcriptome data, we explore 
the functional implications of our top-ranking GWAS results.  
 
Results 
GWAS 
As part of the iPSYCH project10, we collected and genotyped a Danish nation-wide 
population-based case-cohort sample including nearly all individuals born in Denmark 
between 1981 and 2005 and diagnosed with ASD (according to ICD-10) before 2014. We 
randomly selected controls from the same birth cohorts (Table S3.1.1). We have previously 
validated registry-based ASD diagnoses11,12 and demonstrated the accuracy of genotyping 
DNA extracted and amplified from bloodspots collected shortly after birth13,14. Genotypes 
were processed using Ricopili15, performing stringent quality control of data, removal of 
related individuals, exclusion of ancestry outliers based on principal component analysis, 
and imputation using the 1000 Genomes Project phase 3 reference panel. After this 
processing, genotypes from 13,076 cases and 22,664 controls from the iPSYCH sample were 
  
included in the analysis. As is now standard in human complex trait genomics, our primary 
analysis was a meta-analysis of the iPSYCH ASD results with five family-based trio samples 
of European ancestry from the Psychiatric Genomics Consortium (PGC, 5,305 cases and 
5,305 pseudo controls)16. All PGC samples had been processed using the same Ricopili 
pipeline for QC, imputation and analysis as employed here.  
 
Supporting the consistency between the study designs, the iPSYCH population-based and 
PGC family-based analyses showed a high degree of genetic correlation with 𝑟𝐺 = 0.779 (SE 
= 0.106; P = 1.75 x 10-13), similar to the genetic correlations observed between datasets in 
other mental disorders17. Likewise, polygenicity as assessed by polygenic risk scores (PRS) 
showed consistency across the samples supporting homogeneity of effects across samples 
and study designs (see the results below regarding PRS on a five-way split of the sample).  
The SNP heritability (ℎ𝐺
2 ) was estimated to be 0.118 (SE = 0.010, for a population 
prevalence of 0.01218. 
 
The main GWAS meta-analysis totaled 18,381 ASD cases and 27,969 controls, and applied 
an inverse variance-weighted fixed effects model.  To ensure that the analysis was well-
powered and robust, we examined markers with minor allele frequency (MAF) ≥ 0.01, 
imputation INFO score ≥ 0.7, and supported by an effective sample size in >70% of the total. 
This final meta-analysis included results for 9,112,387 autosomal markers and yielded 93 
genome-wide significant markers in three separate loci (Figure 1; Table 1a; Figures S4.1.1-
4.1.44).  Each locus was strongly supported by both the Danish case-control and the PGC 
family-based data. While modest inflation was observed (lambda=1.12, lambda1000 = 
1.006), LD score regression analysis19 indicates this is arising from polygenicity (> 96%, see 
  
Methods) rather than confounding. The strongest signal among 294,911 markers analyzed on 
chromosome X was P = 7.8 x 10-5. 
 
<< Figure 1 and Table 1 goes approximately here>> 
 
We next obtained replication data for the top 88 loci with p-values < 1x10-5 in five cohorts 
of European ancestry totaling 2,119 additional cases and 142,379 controls (Table S3.1.2). 
An overall replication of direction of effects was observed (53 of 88 (60%) of P < 1x10-5; 16 
of 23 (70%) at P < 1x10-6; sign tests P=0.035 and P=0.047, respectively) and two additional 
loci achieved genome-wide significance in the combined analysis (Table 1a). More details 
on the identified loci can be found in Table S3.2.2 and selected candidates are described in 
Box1. 
 
<< Box 1 goes approximately here>> 
 
Correlation with other traits and multi-trait GWAS  
To investigate the extent of genetic overlap between ASD and other phenotypes we 
estimated the genetic correlations with a broad set of psychiatric and other medical diseases, 
disorders, and traits available at LD Hub65 using bivariate LD score regression (Figure 2, 
Table S3.2.3). Significant correlations were found for several traits including 
schizophrenia15 (𝑟𝐺 = 0.211, p = 1.03 x 10
-5) and measures of cognitive ability, especially 
educational attainment20 (𝑟𝐺 = 0.199, p = 2.56 x 10
-9), indicating a substantial genetic 
overlap with these phenotypes and corroborating previous reports5,66-68. In contrast to 
previous reports16, we found a strong and highly significant correlation with major 
depression21 (𝑟𝐺 = 0.412, p = 1.40 x 10
-25), and we are the first to report a prominent overlap 
  
with ADHD69 (𝑟𝐺 = 0.360, p = 1.24 x 10
-12). Moreover, we confirm the genetic correlation 
with social communication difficulties at age 8 in a non-ASD population sample reported 
previously based on a subset of the ASD sample70 (𝑟𝐺 = 0.375, p = 0.0028). 
 
<< Figure 2 goes approximately here>> 
 
In order to leverage these observations for the discovery of loci that may be shared between 
ASD and these other traits, we selected three particularly well-powered and genetically 
correlated phenotypes. These were schizophrenia (N = 79,641)15, major depression (N = 
424,015)21 and educational attainment (N = 328,917)20. We utilized the recently introduced 
MTAG method9 which, briefly, generalizes the standard inverse-variance weighted meta-
analysis for multiple phenotypes. In this case, MTAG takes advantage of the fact that, given 
an overall genetic correlation between ASD and a second trait, the effect size estimate and 
evidence for association to ASD can be improved by appropriate use of the association 
information from the second trait. The results of these three ASD-anchored MTAG scans are 
correlated to the primary ASD scan (and to each other) but given the exploration of three 
scans, we utilized a more conservative threshold of 1.67 x 10-8 for declaring significance 
across these secondary scans giving an estimated maximum false discovery rate (maxFDR) 
of 0.021. In addition to stronger evidence for several of the ASD hits defined above, variants 
in seven additional regions achieved genome-wide significance, including three loci shared 
with educational attainment and four shared with major depression (Table 1b, Box 1, Table 
S3.2.4, Figures S4.1.49-S4.1.55). We note that in these seven instances, the effect size 
estimate is stronger in ASD than the secondary trait, that the result is not characteristic of the 
strongest signals in these other scans (Tables S3.2.5-7) (and in fact 3 of these 7 were not 
significant in the secondary trait and constitute potentially novel findings). Moreover, we 
  
benchmarked against MTAG running two very large and heritable traits (height74, 
n=252,288, and BMI24, n=322,154) with no expected links to ASD and no significant loci 
were added to the list of ASD-only significant associations. 
 
Gene and gene-set analysis 
Next, we performed gene-based association analysis on our primary ASD meta-analysis 
using MAGMA75, testing for the joint association of all markers within a locus (across all 
protein-coding genes in the genome). This analysis identified 15 genes surpassing the 
significance threshold (Table S3.2.8). As expected, the majority of these genes were located 
within the genome-wide significant loci identified in the GWAS, but seven genes are located 
in four additional loci including KCNN2, MMP12, NTM and a cluster of genes on 
chromosome 17 (KANSLl, WNT3, MAPT and CRHRl) (Figures S4.1.57-71). In particular, 
KCNN2 was strongly associated (P = 1.02x10-9), far beyond even single-variant statistical 
thresholds and is included in the descriptions in Box 1. 
 
Enrichment analyses using gene co-expression modules from human neocortex 
transcriptomic data (M13, M16 and M17 from Parikshak et al. 201376 and loss-of-function 
intolerant genes (pLI > 0.9)77,78, which previously have shown evidence of enrichment in 
neurodevelopmental disorders69,76,79, yielded only nominal significance for the latter 
(P=0.014) and M16 (P=0.050) (Table S3.2.9). Genes implicated in ASD by studies or rare 
variants in Sanders et al.56 was just shy of showing nominally significant enrichment 
(P=0.063) while enrichment in the curated gene list from the SPARK consortium80 was 
significant (P=0.0034). Likewise analysis of Gene Ontology sets81,82 for molecular function 
from MsigDB83 revealed no significant sets after Bonferroni correction for multiple testing 
(Table S3.2.10).   
  
 
Dissection of the polygenic architecture 
As ASD is a highly heterogeneous disorder, we explored how ℎ𝐺
2  partitioned across 
phenotypic sub-categories in the iPSYCH sample and estimated the genetic correlations 
between these groups using GCTA84. We examined cases with and without intellectual 
disability (ID, N = 1,873) and the ICD-10 diagnostic sub-categories: childhood autism 
(F84.0, N = 3,310), atypical autism (F84.1, N = 1,607), Asperger’s syndrome (F84.5, N = 
4,622), and other/unspecified pervasive developmental disorders (PDD, F84.8-9, N = 5,795), 
reducing to non-overlapping groups when doing pairwise comparisons (see Table S3.3.1). 
While the pairwise genetic correlations were consistently high between all sub-groups (95% 
CIs including 1 in all comparisons), the ℎ𝐺
2  of Asperger’s syndrome (ℎ𝐺
2  = 0.097, SE = 
0.001) was found to be twice the ℎ𝐺
2  of both childhood autism (ℎ𝐺
2  = 0.049, SE = 0.009, P = 
0.001) and the group of other/unspecified PDD (ℎ𝐺
2  = 0.045, SE = 0.008, P = 0.001) (Table 
S3.3.2 and S3.3.3, Figure S4.2.1 and S4.2.2). Similarly, the ℎ𝐺
2  of ASD without ID (ℎ𝐺
2  = 
0.086, SE = 0.005) was found to be three times higher than for cases with ID (ℎ𝐺 
2 = 0.029, SE 
= 0.013, P = 0.015).  
 
To further examine the apparent polygenic heterogeneity across subtypes, we investigated 
how PRS trained on different phenotypes were distributed across distinct ASD subgroups. 
We focused on phenotypes showing strong genetic correlation with ASD (e.g., educational 
attainment), but included also traits with little or no correlation to ASD (e.g., BMI) as 
negative controls. In this analysis, we regressed the normalized scores on ASD subgroups 
while including covariates for batches and principal components in a multivariate regression. 
Of the eight phenotypes we evaluated, only the cognitive phenotypes showed strong 
heterogeneity (educational attainment20 P = 1.8 x 10-8, IQ23 P = 3.7 x 10-9) (Figure S4.2.3). 
  
Interestingly, all case-control groups with or without ID showed significantly different 
loading for the two cognitive phenotypes: controls with ID have the lowest score followed 
by ASD cases with ID, and ASD cases without ID have significantly higher scores again 
than any other group (P = 2.6 x 10-12 for educational attainment, P = 8.2 x 10-12 for IQ). 
 
With respect to the diagnostic sub-categories constructed hierarchically from ASD subtypes 
(Table S3.3.1), it was again the cognitive phenotypes that showed the strongest 
heterogeneity across the diagnostic classes (educational attainment P = 2.6 x 10-11, IQ P = 
3.4 x 10-8), while neuroticism67 (P = 0.0015), chronotype73 (P = 0.011) and subjective well-
being67 (P = 0.029) showed weaker but nominally significant degree of heterogeneity, and 
SCZ, MDD and BMI24 were non-significant across the groups (P > 0.19) (Figure 3). This 
pattern weakened only slightly when excluding subjects with ID (Figure S4.2.4). For 
neuroticism there was a clear split with atypical and other/unspecified PDD cases having 
significantly higher PRS than childhood autism and Asperger’s, P = 0.00013. Considering 
the genetic overlap of each subcategory with each phenotype, the hypothesis of homogeneity 
across sub-phenotypes was strongly rejected (P = 1.6 x 10-11), thereby establishing that these 
sub-categories indeed have differences in their genetic architectures.  
 
<< Figure 3 goes approximately here>> 
 
Focusing on educational attainment, significant enrichment of PRS was found for Asperger’s 
syndrome (P = 2.0 x 10-17) in particular, and for childhood autism (P = 1.5 x 10-5), but not 
for the group of other/unspecified PDD (P = 0.36) or for atypical autism (P = 0.13) (Figure 
3). Excluding individuals with ID only changes this marginally, with atypical autism 
becoming nominally significant (P = 0.020) (Figure S4.2.4). These results reveal that the 
  
genetic architecture underlying educational attainment is indeed shared with ASD but to a 
variable degree across the disorder spectrum. We find that the observed excess in ASD 
subjects of alleles positively associated with education attainment85,86 is confined to 
Asperger’s and childhood autism, and it is not seen here in atypical autism nor in 
other/unspecified PDD. 
 
Finally, we evaluated the predictive ability of ASD PRS using five different sets of target 
and training samples within the combined iPSYCH-PGC sample. The observed mean 
variance explained by PRS (Nagelkerke’s R2) was 2.45% (P = 5.58 x 10-140) with a pooled 
PRS-based case-control odds ratio OR = 1.33 (CI.95% 1.30 –1.36) (Figures S4.2.8 and 
S4.2.10). Dividing the target samples into PRS decile groups revealed an increase in OR 
with increasing PRS. The OR for subjects with the highest PRS increased to OR = 2.80 
(CI.95% 2.53–3.10) relative to the lowest decile (Figures 4a and S4.2.11). Leveraging 
correlated phenotypes in an attempt to improve prediction of ASD, we generated a multi-
phenotype PRS as a weighted sum of phenotype specific PRS (see Methods). As expected, 
Nagelkerkes’s R2 increased for each PRS included attaining its maximum at the full model at 
3.77% (P = 2.03 x 10-215) for the pooled analysis with an OR = 3.57 (CI.95% 3.22-3.96) for 
the highest decile (Figures 4b and S4.2.12-13). These results demonstrate that an 
individual’s ASD risk depends on the level of polygenic burden of thousands of common 
variants in a dose-dependent way, which can be reinforced by adding SNP-weights from 
ASD correlated traits. 
 
<< Figure 4 goes approximately here>> 
 
Functional annotation 
  
In order to obtain information on possible biological underpinnings of our GWAS results we 
conducted several analyses. First, we examined how the ASD ℎ𝐺
2  partitioned on functional 
genomic categories as well as on cell type-specific regulatory elements using stratified LD 
score regression87. This analysis revealed significant enrichment of heritability in conserved 
DNA regions and H3K4me1 histone marks88, as well as in genes expressed in central 
nervous system (CNS) cell types as a group (Figures S4.2.14 and S4.2.15), which is in line 
with observations in schizophrenia15, major depression21, and bipolar disorder66. Analyzing 
the enhancer associated mark H3K4me1 in individual cell/tissue88, we found significant 
enrichment in brain and neuronal cell lines (Figure S4.2.16).  The highest enrichment was 
observed in the developing brain, germinal matrix, cortex-derived neurospheres, and 
embryonic stem cell (ESC)-derived neurons, consistent with ASD as a neurodevelopmental 
disorder with largely prenatal origins, as supported by data from analysis of rare de novo 
variants76. 
 
Common variation in ASD is located in regions that are highly enriched with regulatory 
elements predicted to be active in human corticogenesis (Figures S4.2.14-16). Since most 
gene regulatory events occur at a distance via chromosome looping, we leveraged Hi-C data 
from germinal zone (GZ) and post-mitotic zones cortical plate (CP) in the developing fetal 
brain to identify potential target genes for these variants89. We performed fine mapping of 28 
loci to identify the set of credible variants containing likely causal genetic risk90 (see 
Methods). Credible SNPs were significantly enriched with enhancer marks in the fetal brain 
(Figure S4.3.1), again confirming the likely regulatory role of these SNPs during brain 
development.   
Based on location or evidence of physical contact from Hi-C, the 380 credible SNPs (28 
loci) could be assigned to 95 genes (40 protein-coding), including 39 SNPs within promoters 
  
that were assigned to 9 genes, and 16 SNPs within the protein coding sequence of 8 genes 
(Table S3.4.1, Figure S4.3.1). Hi-C identified 86 genes, which interacted with credible 
SNPs in either the CP or GZ during brain development. Among these genes, 34 are 
interacting with credible SNPs in both CP and GZ, which represent a high-confidence gene 
list. Notable examples are illustrated in Figure 5 and highlighted in Box 1. By analyzing 
their mean expression trajectory, we observed that the identified ASD candidate genes 
(Table S3.4.1) show highest expression during fetal corticogenesis, which is in line with the 
enrichment of heritability in the regulatory elements in developing brain (Figure 5e-g). 
Interestingly, both common and rare variation in ASD preferentially affects genes expressed 
during corticogenesis76, highlighting a potential spatiotemporal convergence of genetic risk 
on this specific developmental epoch, despite the disorder’s profound genetic heterogeneity.   
 
<< Figure 5 goes approximately here>> 
 
Discussion 
The high heritability of ASD has been recognized for decades and remains among the 
highest for any complex disease despite many clinical diagnostic changes over the past 30-
40 years resulting in a broader phenotype that characterizes more than 1% of the population. 
While early GWAS permitted estimates that common polygenic variation should explain a 
substantial fraction of the heritability of ASD, individually significant loci remained elusive. 
This was suspected to be due to limited sample size since studies of schizophrenia – with 
similar prevalence, heritability and reduced fitness – and major depression achieved striking 
results only when sample sizes five to ten times larger than available in ASD were 
employed. This study has finally borne out that expectation with definitively demonstrated 
significant “hits”. 
  
 
Here we report the first common risk variants robustly associated with ASD by using unique 
Danish resources in conjunction with results of the earlier PGC data – more than tripling the 
previous largest discovery sample.  Of these, five loci were defined in ASD alone, and seven 
additional suggested at a stricter threshold utilizing GWAS results from three correlated 
phenotypes (schizophrenia, depression and educational attainment) and a recently introduced 
analytic approach, MTAG. Both genome-wide LD score regression analysis and the fact that 
even among the loci defined in ASD alone there was additional evidence in these other trait 
scans indicate that the polygenic architecture of ASD is significantly shared with risk to 
adult psychiatric illness and higher educational attainment and intelligence. It should be 
noted that the MTAG analyses were carried out as three pairwise analyses. This way we 
avoid the complex interactions that could arise if we ran three or four correlated phenotypes 
at a time9. Indeed, what we get, despite the secondary summary statistics coming from large, 
high-powered studies, are relatively modest weights to the contributions from these statistics, 
because the genetic correlations are modest. The largest weight was 0.27 for schizophrenia, 
followed by 0.24 for major depression, and 0.11 for educational attainment. Moreover, the 
estimated worst case FDR was just 0.021 up just 0.001 from that of the ASD GWAS alone. 
Thus all loci identified by MTAG were found with an acceptable degree of certainty and 
have substantial contributions from ASD alone (Table 1a, b and S3.2.4). Our expectation is 
that most or all such loci will likely be identified in future ASD-only GWAS as sample sizes 
are increased substantially – however, given how new these methods are, the precise 
phenotypic consequences of these particular variants awaits expansion of all these trait 
GWAS.  
 
  
In most GWAS studies there has been little evidence of heterogeneity of association across 
phenotypic subgroups.  In this study, however, we see strong heterogeneity of genetic 
overlap with other traits when our ASD samples are broken into distinct subsets.  In 
particular, the excess of alleles associated with higher intelligence and educational 
attainment was only observed in the higher functioning categories (particularly Asperger’s 
syndrome and individuals without comorbid ID) – and not in the other/unspecified PDD and 
ID categories.  This is reminiscent, and logically inverted, from the much greater role of 
spontaneous mutations in these latter categories, particularly in genes known to have an even 
larger impact in cohorts ascertained for ID/DD91. Interestingly, other/unspecified PDD and 
atypical autism also have a significantly higher PRS for neuroticism than childhood autism 
and Asperger’s.  These different enrichment profiles observed provide evidence for a 
heterogeneous and qualitatively different genetic architecture between sub-types of ASD, 
which should inform future studies aiming at identifying etiologies and disease mechanisms 
in ASD. 
 
The strong differences in estimated SNP heritability between ASD cases with and without 
ID, and highest in Asperger’s provide genetic evidence of longstanding observations. In 
particular, this aligns well with the observation that de novo variants are more frequently 
observed in ASD cases with ID compared to cases without comorbid ID, that IQ correlates 
positively with family history of psychiatric disorders92 and that severe ID (encompassing 
many syndromes that confer high risk to ASD) show far less heritability than is observed for 
mild ID93, intelligence in general94 and ASDs. Thus it is perhaps unsurprising that our data 
suggests that the contribution of common variants may be more prominent in high-
functioning ASD cases such as Asperger’s syndrome.  
 
  
We further explored the functional implications of these results with complementary 
functional genomics data including Hi-C analyses of fetal brains and brain transcriptome 
data. Analyses at genome-wide scale (partitioned ℎ𝐺
2  (Figures S4.2.14-16) and brain 
transcriptome enrichment (Figure 5e-g)) as well as at single loci (Figure 5a-d, Box 1) 
highlighted the involvement of processes relating to brain development and neuronal 
function. Notably, a number of genes located in the identified loci have previously been 
linked to ASD risk in studies of de novo and rare variants (Box 1, Table S3.2.2), including 
PTBP2, CADPS, and KMT2E, which were found to interact with credible SNPs in the Hi-C 
analysis (PTBP2, CADPS) or contain a loss-of-function credible SNP (KMT2E).  
Interestingly, aberrant splicing of CADPS’ sister gene CADPS2, which has almost identical 
function, has been found in autism cases and Cadps2 knockout mice display behavioral 
anomalies with translational relevance to autism95. PTBP2 encodes a neuronal splicing factor 
and alterations in alternative splicing have been identified in brains from individuals 
diagnosed with ASD96. 
 
In summary, we have established a first compelling set of common variant associations in 
ASD and have begun laying the groundwork through which the biology of ASD and related 
phenotypes will inevitably be better articulated. 
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Figure legends 
 
Figure 1. Manhattans plots: with the x axis showing genomic position (chromosomes 1–22) 
and the y axis showing statistical significance as –log10 (P) of z statistics. a: The main ASD 
scan (18,381 cases and 27,969 controls) with the results of the combined analysis with the 
follow-up sample (2,119 cases and 142,379 controls) in yellow in the foreground. Genome 
wide significant clumps are painted green with index SNPs as diamonds. b-d:  Manhattan 
plots for three MTAG scans of ASD together with, respectively, schizophrenia15 (34,129 cases 
and 45,512 controls), educational attainment20 (N = 328,917) and major depression21 (111,902 
case and 312,113 controls). See Figures S4.1.45-48 for full size plots. In all panels the results 
of the composite of the five analyses (consisting for each marker of the minimal p-value of 
the five) is shown in grey in the background. 
 
 
Figure 2. Genetic correlation with other traits. Significant genetic correlations between 
ASD (N = 46,350) and other traits after Bonferroni correction for testing a total of 234 traits 
available at LDhub with the addition of a handful of new phenotypes. Estimates and tests by 
LDSC19. The results here corresponds to the following GWAS analyses: IQ23 (N = 78,308), 
educational attainment20 (N = 328,917), college71 (N = 111,114), self-reported tiredness72 (N 
= 108,976), neuroticism67 (N = 170,911), subjective well-being67 (N = 298,420), 
schizophrenia15 (N = 82,315), major depression21 (N = 480,359), depressive symptoms67(N = 
161,460), ADHD69 (N = 53,293), and chronotype73 (N = 128,266). See Table S3.2.3 for the 
full output of this analysis. 
* Indicates that the values are from in-house analyses of new summary statistics not yet 
included in LD Hub.  
 
 
Figure 3. Profiling PRS load across distinct ASD sub-groups for 8 different phenotypes 
(schizophrenia15, major depression21, educational attainment20, human intelligence23, 
subjective well-being67, chronotype73, neuroticism67 and BMI24. The bars show coefficients 
from multivariate multivariable regression of the 8 normalized scores on the distinct ASD sub-
types of 13,076 cases and 22,664 controls, adjusting for batches and PCs. The subtypes are 
the hierarchically defined subtypes for childhood autism (hCHA, N = 3,310), atypical autism 
(hATA, N = 1,494), Asperger’s (hAsp, N = 4,417), and the lumped pervasive disorders 
developmental group (hPDM, N = 3,855). Beware that the orientation of the scores for 
subjective well-being, chronotype and BMI have been switched to improve graphical 
  
presentation. The corresponding plot where subjects with ID have been excluded can be seen 
in Figure S4.2.4, and with ID as a subtype in Figure S4.2.3. Applying the same procedure to 
the internally trained ASD score did not display systematic heterogeneity (p=0.068) except as 
expected for the ID groups (p=0.00027) (Figure S4.2.7). Linear hypotheses tested using the 
Pillai test. 
 
 
Figure 4. Decile plots (Odds Ratio (OR) by PRS within each decile for 13,076 cases and 
22,664 controls): a. Decile plot with 95%-CI for the internally trained ASD score (P-value 
threshold is 0.1). b. Decile plots on a weighted sums of PRSs starting with the ASD score of 
panel a and successively adding the scores for major depression21, subjective well-being67, 
schizophrenia15, educational attainment20, and chronotype73. In all instances the P-value 
threshold for the score used is the one with the highest Nagelkerke’s R2. Figures S4.2.11 and 
S4.2.13 show the stability across leave-one out groups that was used to create these combined 
results.  
 
 
Figure 5. Chromatin interactions identify putative target genes of ASD loci. a-d. 
Chromatin interaction maps of credible SNPs to the 1Mb flanking region, providing putative 
candidate genes that physically interact with credible SNPs. Gene Model is based on 
Gencode v19 and putative target genes are marked in red; Genomic coordinate for a credible 
SNP is labeled as GWAS; -log10(P-value), significance of the interaction between a SNP 
and each 10kb bin, grey dotted line for FDR=0.01 (one-sided significance test calculated as 
the probability of observing a higher contact frequency under the fitted Weibull distribution 
matched by chromosome and distance); TAD borders in CP and GZ. e-f. Developmental 
expression trajectories of ASD candidate genes show highest expression in prenatal periods. 
Significance by t-test (n=410 and 453 for prenatal and postnatal samples, respectively). Box-
plots showing median, interquartile range (IQR) with whiskers adding IQR to the 1st and 3rd 
quartile (e and g). LOESS smooth curve plotted with actual data points (f)  g. ASD candidate 
genes are highly expressed in the developing cortex as compared to other brain regions. One-
way ANOVA and posthoc Tukey test, FDR-corrected. (n=410/453, 39/36, 33/37, 48/34, 
37/36, 32/39 for prenatal/postnatal cortex, hippocampus, amygdala, striatum, thalamus, and 
cerebellum, respectively).   
 
  
 
 
  
Box1. Selected loci and candidates (ordered by chromosome).  
 
Gene Locus* and supporting evidence 
 
Gene function  
 
NEGR1 Chr1:72,729,142 
Shared ASD-MDD locus 
Locus also significant in depression21,22, educational attainment20, intelligence23, obesity and 
BMI24-28 and in an ASD-schizophrenia meta-analysis5. 
NEGR1 is the only protein-coding gene in the locus  
NEGR1 is supported by brain Hi-C and eQTL analyses21 
NEGR1 (neuronal growth regulator 1) is an adhesion molecule modulating synapse formation in 
hippocampal neurons29,30 and neurite outgrowth31,32. It is member of the IgLON protein family 
implicated in synaptic plasticity and axon extension33-35. 
Predominantly expressed (and developmentally upregulated) in hippocampus and cortex36 and 
also hypothalamus37.  
PTBP2 Chr1:96,561,801 
ASD locus 
Locus also significant in BMI24,25,27 ,weight25 and educational attainment20. In schizophrenia the 
locus shows a p-value of 6.5x10-6 15 
PTBP2 is the nearest protein-coding gene, approx. 625kb from index SNP. 
De novo and rare variants in PTBP2 have been reported in ASD cases1,3,38.   
PTBP2 is supported by Hi-C results in this study (Fig. 5d) 
PTBP2 is also known as nPTB (neuronal PTB) or brPTB (brain PTB) and is a splicing regulator. PTBP1 
and its paralog PTBP2 bind to intronic polypyrimidine tracts in pre-mRNAs and target large sets of 
exons to coordinate alternative splicing programs during development39. Several switches in the 
expression of PTBP1 and PTBP2 regulate alternative splicing during neurogenesis and neuronal 
differentiation 40-43.  
 
CADPS 
 
Chr3:62,481,063 
Shared ASD-Educational attainment locus 
Locus also significant in study of cognitive decline rate44  
CADPS is supported by Hi-C results in this study (Fig. 5a). 
CADPS encodes a calcium-binding protein involved in exocytosis of neurotransmitters and 
neuropeptides. In line with CAPDS mRNA being mainly expressed in brain and pituitary 
(gtexportal), immunoreactive CAPS-1 is localized in neural and various endocrine tissues45. In 
hippocampal synapses, CADPS regulates the pool of readily releasable vesicles at pre-synaptic 
terminals46,47  
KCNN2 Chr5: 113,801,423 
ASD locus (gene-wise analysis) 
Locus also significant in educational attainment20,48.  
KCNN2 synaptic levels are regulated by the E3 ubiquitin ligase UBE3A49, of which overexpression 
has been linked to ASD risk49,50. 
KCNN2 is a voltage-independent Ca2+-activated K+ channel that responds to changes in intracellular 
calcium concentration and couples calcium metabolism to potassium flux and membrane 
excitability. In CNS neurons, activation of KCNN2 modulates neuronal excitability by causing 
membrane hyperpolarization51. Hippocampal KCNN2 has roles in the formation of new memory52, 
encoding and consolidation of contextual fear53, and in drug-induced plasticity54. 
KMT2E Chr7:104,744,219 
ASD locus  
Locus also significant in schizophrenia15,55 and in ASD-schizophrenia meta-analysis5. 
KMT2E de novo mutations are associated with ASD at FDR<0.156  
KMT2E encodes Histone-lysine N-methyltransferase 2E and forms a family together with 
SETD557,58. Evidence suggest that recognition of the histone H3K4me3 mark by the KMT2E PHD 
finger can facilitate the recruitment of KMT2E to transcription-active chromatin regions59,60. KMT2E 
has been implicated in chromatin regulation, control of cell cycle progression, and maintaining 
genomic stability61.  
  
A KMT2E credible SNP is a loss-of-function variant (Table S3.4.1) 
MACROD2 Chr20: 14836243 
ASD locus 
Locus found significant in previous ASD GWAS62 but not supported in larger study63  
MACROD2 is the only protein-coding gene in the locus 
MACROD2 is a nuclear enzyme that binds to mono-ADP-ribosylated (MARylated) proteins and 
functions as an eraser of mono-ADP-ribosylation64. Intracellular MARylated histones and GSK3β are 
substrates of MACROD2, and the removal of MAR from GSK3β is responsible for reactivating of its 
kinase activity64. This gene is expressed in lung and multiple regions of the brain. Low or no 
expression across most other tissue (https://www.gtexportal. org).  
*position of index SNP is listed.  
 
 
  
  
Table 1. Genome-wide significant loci from ASD scans and MTAG analyses. Panel a shows the loci reaching genome-wide significance in 
analysis of the ASD phenotype alone. The column “Analysis” indicates the minimum p-value arising from the original scan (ASD) and the combined 
analysis with the follow-up sample (Comb ASD). The columns “Support from other scans” list the other analyses (including MTAG) that further 
support the locus at genomewide significance. For the ASD scan results, this shows the genome-wide significant results in the locus from the other 
scans, and for Comb ASD it displays the result from ASD. Panel b presents additional genome-wide significant loci identified in the three MTAG 
analyses.  The three analyses are ASD with schizophrenia (SCZ)15, educational attainment (Edu)20 and major depression (MD)21. Here the “Analysis” 
column points to which MTAG analysis gave the results (ASD-Edu or ASD-MD), and the columns “Support from other scans” provide the 
corresponding scan results in ASD alone. In both panels, independent loci are defined to have r2 < 0.1 and distance > 400kb and the index variant is 
displayed in the column “Index var”. Other columns are: chromosome (CHR), chromosomal position (BP), alleles (A1/A2), allele frequency of A1 
(FRQ), estimate of effect (β) with respect to A1, standard error of β (SE), and the association p-value of the index variant (P). The column “Nearest 
genes” lists nearest genes from within 50kb of the region spanned by all SNPs with r2≥0.6 to the index variant.   
* Indicate different lead SNP than the index variant 
  
Index var CHR BP Analysis P β SE A1/A2 FRQ Support from other scans Nearest genes 
 Scan P β  
a rs910805 20 21248116 ASD 2.04 x 10-9 -0.096 0.016 A/G 0.76 ASD-SCZ 1.5 x10-10 -0.069  KIZ, XRN2, NKX2-2, NKX2-4 
          ASD-Edu* 2.0 x10-8 -0.061   
rs10099100 8 10576775 ASD 1.07 x 10-8 0.084 0.015 C/G 0.331 Comb ASD 9.6 x 10-9 0.078  C8orf74, SOX7, PINX1 
          ASD-Edu 1.6 x 10-8 0.056    
rs201910565 1 96561801 Comb ASD 2.48 x 10-8 -0.077 0.014 A/AT 0.689 ASD 3.4 x 10-7 -0.033 LOC102723661, PTBP2  
rs71190156 20 14836243 ASD 2.75 x 10-8 -0.078 0.014 GTTTT 0.481 Comb ASD 3.0 x 10-8 -0.072  MACROD2 
        TTT/G  ASD-Edu 1.2 x 10-8 0.053   
rs111931861 7 104744219 Comb ASD 3.53 x 10-8 -0.216 0.039 A/G 0.966 ASD 1.1 x 10-7 -0.094 KMT2E, SRPK2  
  
 
 
     
   
 
b rs2388334 6 98591622 ASD-Edu 3.34 x 10-12 -0.065 0.009 A/G 0.517 ASD 1.0 x 10-6 -0.068 MMS22L, POU3F2  
rs325506 5 104012303 ASD-MD 3.26 x 10-11 0.057 0.009 C/G 0.423 ASD 3.5 x 10-7 0.071 NUD12 
 
rs11787216 8 142615222 ASD-Edu 1.99 x 10-9 -0.058 0.010 T/C 0.364 ASD 2.6 x 10-6 -0.030 MROH5 
 
rs1452075 3 62481063 ASD-Edu 3.17 x 10-9 0.061 0.010 T/C 0.721 ASD 2.1 x 10-7 0.035 CADPS 
 
rs1620977 1 72729142 ASD-MD 6.66 x 10-9 0.056 0.010 A/G 0.26 ASD 1.2 x 10-4 0.062 NEGR1 
  
 
rs10149470 14 104017953 ASD-MD 8.52 x 10-9 -0.049 0.008 A/G 0.487 ASD 8.5 x 10-5 -0.056 MARK3, CKB, TRMT61A, 
BAG5, APOPT1, KLC1, 
XRCC3 
  rs16854048 4 42123728 ASD-MD 1.29 x 10-8 0.069 0.012 A/C 0.858 ASD 5.9 x 10-5 0.082 SLC30A9, BEND4, TMEM33, 
DCAF4L1 
  
Methods 
Subjects 
iPSYCH sample 
The iPSYCH ASD sample is a part of a population based case-cohort sample extracted from a 
baseline cohort10 consisting of all children born in Denmark between May 1st 1981 and December 
31st 2005. Eligible were singletons born to a known mother and resident in Denmark on their one-
year birthday. Cases were identified from the Danish Psychiatric Central Research Register 
(DPCRR)12, which includes data on all individuals treated in Denmark at psychiatric hospitals 
(from 1969 onwards) as well as at outpatient psychiatric clinics (from 1995 onwards). Cases were 
diagnosed with ASD in 2013 or earlier by a psychiatrist according to ICD10, including diagnoses of 
childhood autism (ICD10 code F84.0), atypical autism (F84.1), Asperger’s syndrome (F84.5), other 
pervasive developmental disorders (F84.8), and pervasive developmental disorder, unspecified 
(F84.9). As controls we selected a random sample from the set of eligible children excluding those 
with an ASD diagnosis by 2013. 
 
The samples were linked using the unique personal identification number to the Danish Newborn 
Screening Biobank (DNSB) at Statens Serum Institute (SSI), where DNA was extracted from 
Guthrie cards and whole genome amplified in triplicates as described previously13,97. Genotyping 
was performed at the Broad Institute of Harvard and MIT (Cambridge, MA, USA) using the 
PsychChip array from Illumina (CA, San Diego, USA) according to the instructions of the 
manufacturer. Genotype calling of markers with minor allele frequency (maf) > 0.01 was performed 
by merging callsets from GenCall98 and Birdseed99 while less frequent variants were called with 
zCall100. Genotyping and data processing was carried out in 23 waves.  
 
  
All analyses of the iPSYCH sample and joint analyses with the PGC samples were performed at the 
secured national GenomeDK high performance-computing cluster in Denmark.  
 
The study was approved by the Regional Scientific Ethics Committee in Denmark and the Danish 
Data Protection Agency. 
 
Psychiatric Genomic Consortium (PGC) samples 
In brief, five cohorts provided genotypes to the sample (n denoting the number of trios for which 
genotypes were available): The Geschwind Autism Center of Excellence (ACE; N = 391), the 
Autism Genome Project62 (AGP; N = 2272), the Autism Genetic Resource Exchange101,102 (AGRE; 
N = 974), the NIMH Repository, the Montreal103/Boston Collection (MONBOS; N = 1396, and the 
Simons Simplex Collection 104,105(SSC; N = 2231). The trios were analyzed as cases and pseudo 
controls. A detailed description of the sample is available on the PGC web site and even more 
details are provided in Anney et al5. Analyses of the PGC genotypes were conducted on the 
computer cluster LISA at the Dutch HPC center SURFsara.  
 
Follow-up samples 
As follow-up for the loci with p-values less than 10-6 we asked for look up in 5 samples of Nordic 
and Eastern European origin with altogether 2,119 cases and 142,379 controls: BUPGEN (Norway: 
164 cases and 656 controls), PAGES (Sweden: 926 cases and 3,841 controls not part of the PGC 
sample above), the Finnish autism case-control study (Finland: 159 cases and 526 controls), 
deCODE (Iceland 574 cases and 136,968 controls; Eastern Europe: 296 cases and 388 controls). 
See supplementary for details. 
 
  
Statistical analyses 
All statistical test are two-sided unless otherwise stated. Software versions etc. can be found in Life 
Sciences Reporting Summary.  
 
GWAS analysis 
Ricopili15, the pipeline developed by the Psychiatric Genomics Consortium (PGC) Statistical 
Analysis Group was used for quality control, imputation, principle component analysis (PCA) and 
primary association analysis. For details see supplementary information. The data was processed 
separately in the 23 genotyping batches in the case of iPSYCH and separately for each study in the 
PGC sample. Phasing was achieved using SHAPEIT106 and imputation done by IMPUTE2107,108 
with haplotypes from the 1000 Genomes Project, phase 3109 (1kGP3) as reference.  
 
After excluding regions of high LD110, the genotypes were pruned down to a set of roughly 30k 
markers. See supplementary information for details. Using PLINK’s111 identity by state analysis 
pairs of subjects were identified with ?̂? > 0.2 and one subject of each such pair was excluded at 
random (with a preference for keeping cases). PCA was carried out using smartPCA112,113. In 
iPSYCH a subsample of European ancestry was selected as an ellipsoid in the space of PC1-3 
centred and scaled using the mean and 8 standard deviation of the subsample whose parents and 
grandparents were all known to have been born in Denmark (n=31500). In the PGC sample the 
CEU subset was chosen using a Euclidian distance measure weighted by the variance explained by 
each of the first 3 PCs. Individuals more distant than 10 standard deviations from the combined 
CEU and TSI HapMap reference populations were excluded. We conducted a secondary PCA on 
the remaining 13,076 cases and 22,664 control to provide covariates for the association analyses. 
  
Numbers of subjects in the data generation flow for the iPSYCH sample are found in the descriptive 
table Table S3.1.1. 
 
Association analyses were done by applying PLINK 1.9 to the imputed dosage data (the sum of 
imputation probabilities P(A1A2) + 2P(A1A1)). In iPSYCH we included the first four principal 
components (PCs) as covariates as well as any PC beyond that, which were significantly associated 
with ASD in the sample, while the case-pseudo-controls from the PGC trios required no PC 
covariates. Combined results for iPSYCH and for iPSYCH with the PGC was achieved by meta-
analysing batch-wise and study-wise results using METAL114 (July 2010 version) employing an 
inverse variance weighted fixed effect model115. On chromosome X males and females were 
analyzed separately and then meta-analyzed together. Subsequently we applied a quality filter 
allowing only markers with an imputation info score ≥ 0.7, maf ≥ 0.01 and an effective sample 
size (see supplementary info) of at least 70% of the study maximum. The degree to which the 
deviation in the test statistics can be ascribed to cryptic relatedness and population stratification 
rather than to polygenicity was measured from the intercept in LD score regression19 (LDSC) as the 
ratio of (intercept-1) and (mean(χ2)-1). 
MTAG9 was applied with standard settings. The iPSYCH-PGC meta-analysis summary statistics 
was paired up with the summary statistics for each of major depression21 (excluding the Danish 
sampled but including summary statistics from 23andMe22, 111,902 cases, 312,113 controls, and 
mean χ2=1.477), schizophrenia15 (also excluding the Danish samples, 34,129 cases, 45,512 controls, 
and mean χ2=1.804) and educational attainment20 (328,917 samples and mean χ2=1.648). These are 
studies that have considerably more statistical power than the ASD scan, but the genetic 
correlations are modest in the context of MTAG, so the weights ascribed to the secondary 
  
phenotypes in the MTAG analyses remain relatively low (no higher than 0.27). The maximum FDR 
was estimated as recommended in the MTAG paper9. See supplementary notes for details.  
The results were clumped and we highlighted loci of interest by selecting those that were significant 
at 5 x 10-8 in the iPSYCH-PGC meta-analysis or the meta-analysis with the follow-up sample or 
were significant at 1.67 x l0-8 in any of the three MTAG analyses. The composite GWAS consisting 
of the minimal p-values at each marker over these five analyses was used as a background when 
creating Manhattan plots for the different analyses showing both what is maximally achieved and 
what the individual analysis contributes to that.  
 
Gene-based association and gene-set analyses.  
MAGMA 1.0675 was applied to the ASD GWAS summary statistics to test for gene-based 
association. Using NCBI 37.3 gene definitions and restricting the analysis to SNPs located within 
the transcribed region, mean SNP association was tested with the sum of -log(SNP p-value) as test 
statistic. The resulting gene-based p-values were further used in competitive gene-set enrichment 
analyses in MAGMA. One analysis explored the candidate sets M13, M16 and M17 from Parikshak 
et al. 201376, constrained, loss-of-function intolerant genes (pLI>0.9)77,78 derived from data of the 
Exome Aggregation Consortium (see supplementary notes for details), as well as gene sets found in 
studies of rare variants in autism by Sanders et al.56 and the curated gene list from the SPARK 
consortium80. Another was an agnostic analysis of the Gene Ontology sets81,82 for molecular 
function from MsigDB 6.083. We analyzed only genes outside the broad MHC region 
(hg19:chr6:25-35M) and included only gene sets with 10-1000 genes. The gene set from Sanders et 
al. and SPARK include only one gene in MHC and was exempt from the MHC exclusion to be as 
true to the set as possible. All gene sets with significant enrichment were inspected to ensure that 
the signal was not driven by one or a few associated loci with multiple genes in close LD.  
  
SNP heritability  
SNP heritability, ℎ𝐺
2 , was estimated using LDSC19 for the full ASD GWAS sample and 
GCTA84,116,117 for subsamples too small for LDSC. For LDSC we used precomputed LD scores 
based on the European ancestry samples of the 1000 Genomes Project118 restricted to HapMap3119 
SNPs. The summary stats with standard LDSC filtering were regressed onto these scores. For 
liability scale estimates, we used a population prevalence for Denmark of 1.22%18. Lacking proper 
prevalence estimates for subtypes, we scaled the full spectrum prevalence based on the composition 
of the case sample.  
For subsamples too small for LDSC, the GREML approach of GCTA84,116,117 was used. On best 
guess genotypes (genotype probability > 0.8, missing rate < 0.01 and MAF > 0.05) with INDELs 
removed, a genetic relatedness matrix (GRM) was fitted for the association sample (i.e. the subjects 
of European ancestry with ?̂? ≤ 0.2) providing a relatedness estimate for all pairwise combinations 
of individuals.  Estimation of the phenotypic variance explained by the SNPs (REML) was 
performed including PC 1-4 as continuous covariates together with any other PC that was 
nominally significantly associated to the phenotype as well as batches as categorical indicator 
covariates. Testing equal heritability for non-overlapping groups was done by permutation test 
(with 1000 permutations) keeping the controls and randomly assigning the different case labels. 
 
Following Finucane et al87, we conducted an enrichment analysis of the heritability for SNPs for 
functional annotation and for SNPs located in cell-type-specific regulatory elements. Using first the 
same 24 overlapping functional annotations (stripped down from 53) as in Finucane et al. we 
regressed the 𝜒2 from the ASD GWAS summary statistics on to the cell-type specific LD scores 
download from the site mentioned above with baseline scores, regression weights and allele 
frequencies based on European ancestry 1000 Genome Project data. The enrichment of a category 
  
was defined as the proportion of SNP heritability in the category divided by the proportion of SNPs 
in that category. Still following Finucane et al. we did a similar analysis using 220 cell type–
specific annotations divided into 10 overlapping groups. In addition to this, we conducted an 
analysis based on annotation derived from data on H3K4Me1 imputed gapped peaks data from the 
Roadmap Epigenomics Mapping Consortium120; more specifically information excluding the broad 
MHC-region (chr6:25-35MB).  
 
Genetic correlation 
For the main ASD samples, SNP correlations, 𝑟𝐺 , were estimated using LDSC
19 and for the analysis 
of ASD subtypes and subgroups where the sample sizes were generally small, we used GCTA84. In 
both cases, we followed the same procedures as explained above. For all but a few phenotypes, 
LDSC estimates of correlation were achieved by upload to LD hub65 for comparison to all together 
234 phenotypes.  
 
Polygenic risk scores 
For the polygenic risk scores (PRS) we clumped the summary stats applying standard Ricopili 
parameters (see supplementary notes for details). To avoid potential strand conflicts we excluded all 
ambiguous markers for summary statistics not generated by Ricopili using the same imputation 
reference. PRS were generated at the default p-value thresholds (5e-8, 1e-6, 1e-4, 0.001, 0.01, 0.05, 
0.1, 0.2, 0.5 and 1) as a weighted sum of the allele dosages in the ASD GWAS sample. Summing 
over the markers abiding by the p-value threshold in the training set and weighing by the additive 
scale effect measure of the marker (log(OR) or β) as estimated in the training set. Scores were 
normalized prior to analysis.  
 
  
We evaluated the predictive power using Nagelkerke’s 𝑅2 and plots of odds ratios and confidence 
intervals over score deciles. Both 𝑅2 and odds ratios were estimated in regression analyses 
including the relevant PCs and indicator variables for genotyping waves.  
 
Lacking a large ASD sample outside of iPSYCH and PGC, we trained a set of PRS for ASD 
internally in the following way. We divided the sample in five subsamples of roughly equal size 
respecting the division into batches. We then ran five GWAS leaving out each group in turn from 
the training set and meta-analyzed these with the PGC results. This produced a set of PRS for each 
of the five subsamples trained on their complement. Prior to analyses, each score was normalized 
on the group where it was defined. We evaluated the predictive power in each group and on the 
whole sample combined. 
 
To exploit the genetic overlap with other phenotypes to improve prediction, we created a series of 
new PRS by adding to the internally trained ASD score the PRS of other highly correlated 
phenotypes in a weighted sum. See supplementary info for details.  
 
To analyze ASD subtypes in relation to PRS we defined a hierarchical set of phenotypes in the 
following way: First hierarchical subtypes was childhood autism, hierarchical atypical autism was 
defined as everybody with atypical autism and no childhood autism diagnosis, hierarchical 
Asperger’s as everybody with an Asperger’s diagnosis and neither childhood autism nor atypical 
autism. Finally we lumped other pervasive developmental disorders and pervasive developmental 
disorder, unspecified into pervasive disorders developmental mixed, and the hierarchical version of 
that consists of everybody with such a diagnosis and none of the preceding ones (Table S3.3.1). We 
examined the distribution over the distinct ASD subtypes of PRS for a number of phenotypes 
  
showing high 𝑟𝐺 with ASD (as well as a few with low 𝑟𝐺 as negative controls), by doing 
multivariate regression of the scores on the subtypes while adjusting for relevant PCs and wave 
indicator variables in a linear regression. See supplementary notes for details.   
 
Hi-C analysis 
The Hi-C data was generated from two major cortical laminae: the germinal zone (GZ), containing 
primarily mitotically active neural progenitors, and the cortical and subcortical plate (CP), 
consisting primarily of post-mitotic neurons89. We first derived a set of credible SNPs (putative 
causal SNPs) from the identified top ranking loci in the ASD GWAS using CAVIAR90. The 30 loci 
showing the strongest association was intersected with the Hi-C reference data resulting in 28 loci 
for analysis. To test whether credible SNPs are enriched in active marks in the fetal brain120, we 
employed GREAT as previously described89,121. Credible SNPs were sub-grouped into those 
without known function (unannotated) and functionally annotated SNPs (SNPs in the gene 
promoters and SNPs that cause nonsynonymous variants) (Figure S4.3.1). Then we integrated 
unannotated credible SNPs with chromatin contact profiles during fetal corticogenesis89, defining 
genes physically interacting with intergenic or intronic SNPs (Figure S4.3.1).  
 
The spatiotemporal transcriptomic atlas of human brain was obtained from Kang et al122. We used 
transcriptomic profiles of multiple brain regions with developmental epochs that span prenatal (6-
37 post-conception week, PCW) and postnatal (4 months-42 years) periods. Expression values were 
log-transformed and centered to the mean expression level for each sample using a scale(center=T, 
scale=F)+1 function in R. ASD candidate genes identified by Hi-C analyses (Figure S4.3.1) were 
selected for each sample and their average centered expression values were calculated and plotted.  
 
  
Availability of summary statistics 
The summary statistics are available for download the iPSYCH and at the PGC download sites (see 
the URL section). 
Availability of genotype data  
For access to genotypes from the PGC samples and the iPSYCH sample, researchers should contact 
the lead PIs Mark J. Daly and Anders D. Børglum for PGC-ASD and iPSYCH-ASD respectively. 
 
 
URLs 
 
The GenomeDK high performance-computing cluster in Denmark, https://genome.au.dk; the 
iPSYCH project, http://ipsych.au.dk, the iPSYCH download page, http://ipsych.au.dk/downloads/; 
the NIMH Repository, https://www.nimhgenetics.org/available_data/autism/; the PGC download 
site, https://www.med.unc.edu/pgc/results-and-downloads; the LISA cluster at SURFsara, 
https://userinfo.surfsara.nl/systems/lisa; plink 1.9, www.cog-genomics.org/plink/1.9/; the NIMH 
Repository (https://www.nimhgenetics.org/available_data/autism/); LDSC and associated files, 
https://github.com/bulik/ldsc; LD hub, http://ldsc.broadinstitute.org/ldhub/;  
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